
Independent Medical Education
Daiichi Sankyo supports a variety of independent accredited continuing education (CE) activities. The information on this page is intended to provide self-service to educational topics of interest and activities are free to the learner.
Daiichi Sankyo adheres to the commercial support standards established by the Accreditation Council for Continuing Medical Education (ACCME®). The company also complies with the principles established by the Office of Inspector General (OIG) Compliance Guidance to Pharmaceutical Manufacturers and Pharmaceutical Research and Manufacturers of America (PhRMA) Code on Interactions with Medical Professionals Independent Medical Education is independently supported by Daiichi Sankyo without any influence over the education. Responsibility and control over content, faculty, and educational material belong solely to the providers/accreditors of these activities.
Therapeutic Areas
Breast Cancer
How ADCs Are Transforming HER2+ Metastatic Breast Cancer: Discover the Latest Clinical Trend
Activity Enduring from 7-July-2021 through 7-July 2022
Provided by Global Learning Collaborative – Prova Education
Expert Second Opinion: Investigators Discuss Available Clinical Research in the Care of Patients with Challenging Cases of HER2-Positive Breast Cancer
Activity Enduring from 22-June-2021 through 22-June-2022
Provided by Research to Practice
Navigating Shifts in the Treatment Landscape for Metastatic HER2-Positive Breast Cancer: Can New HER2-Targeted Therapies Address Unmet Needs and Offer Better Options for Challenging Patient Populations?
Activity Enduring from 1-Jun-2021 through 31-May-2022
Provided by PeerView Institute
Gastric Cancer
Advanced HER2-Positive Gastric Cancer
Activity Enduring from 13-May-2021 through 13-May-2022
Provided by Prova Education
Adding Trastuzumab Deruxtecan to the Treatment Armamentarium for Advanced Gastric Cancers
Activity Enduring from 15-Feb-2021 through 15-Feb-2022
Provided by Clinical Care Options, LLC
Taking Aim at GI Cancers: New Opportunities to Deliver Personalized Treatment With HER2 and Other Molecularly Targeted Therapies
Activity Enduring from 8-Feb-2021 through 7-Feb-2022
Provided by Medical Learning Institute & PeerView Institute
Hematology
What Clinicians Want To Know: Addressing Current Questions and Controversies in the Management of Acute Myeloid Leukemia and Myelodysplastic Syndromes
Activity Enduring from 21-January-2022 through 21-January-2023
Provided by Research to Practice
Addressing Clinical Challenges in T-Cell Lymphomas Through Biomarker-Driven Therapy
Activity Enduring from 28-December-2021 through 28-December-2022
Provided by Clinical Care Options, LLC